Trial Profile
Phase Ib Trial of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Subjects With Hematologic Malignancies (KEYNOTE-155).
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Dinaciclib (Primary) ; Pembrolizumab (Primary)
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Multiple myeloma
- Focus Adverse reactions
- Acronyms KEYNOTE-155
- Sponsors Merck Sharp & Dohme Corp.
- 19 Jan 2021 Status changed from completed to discontinued.
- 15 Apr 2020 Status changed from active, no longer recruiting to completed.
- 21 Feb 2020 Planned End Date changed from 13 Mar 2020 to 10 Apr 2020.